Penn Capital Management Company LLC Invests $476,000 in Artivion, Inc. $AORT

Key Points

• Penn Capital Management Company LLC acquired 19,362 shares of Artivion, Inc. for approximately $476,000, adding to the trend of institutional investment in the stock.
• Artivion's stock is currently trading at $44.81, having increased by 3.9%, with a market capitalization of $2.11 billion.
• The company recently reported earnings of $0.24 per share, exceeding estimates, with quarterly revenue rising by 15.3% year-over-year to $112.97 million.

Penn Capital Management Company LLC bought a new position in Artivion, Inc. (NYSE:AORT - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,362 shares of the company's stock, valued at approximately $476,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Legacy Advisors LLC bought a new position in shares of Artivion in the first quarter worth about $28,000. MCF Advisors LLC raised its holdings in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after buying an additional 614 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion in the 4th quarter valued at approximately $64,000. Raymond James Financial Inc. bought a new position in Artivion in the 4th quarter valued at approximately $275,000. Finally, EntryPoint Capital LLC bought a new position in Artivion during the 1st quarter worth approximately $284,000. Institutional investors own 86.37% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on AORT. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. JMP Securities raised their price objective on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research report on Friday, August 8th. Stifel Nicolaus lifted their price target on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Needham & Company LLC lifted their price target on shares of Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. Finally, LADENBURG THALM/SH SH downgraded shares of Artivion from a "buy" rating to a "neutral" rating and lifted their price target for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Artivion presently has an average rating of "Buy" and a consensus price target of $40.63.

Insider Buying and Selling

In other Artivion news, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the completion of the transaction, the senior vice president owned 64,200 shares in the company, valued at approximately $2,826,084. This represents a 22.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John E. Davis sold 10,802 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the transaction, the insider owned 208,778 shares of the company's stock, valued at $9,117,335.26. The trade was a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 115,990 shares of company stock worth $4,435,823. 7.60% of the stock is owned by company insiders.

Artivion Stock Performance

Artivion stock traded up $0.01 during midday trading on Friday, reaching $43.82. The stock had a trading volume of 106,383 shares, compared to its average volume of 443,978. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The firm's 50-day moving average price is $34.80 and its 200 day moving average price is $29.22. The firm has a market capitalization of $2.07 billion, a PE ratio of -104.18 and a beta of 1.64. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company's revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, research analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.